Heart Sciences announces that Professor Peter McFarlane has been appointed to the clinical advisory committee

Professor Peter W. McFarlane (DSc eFESC FRSE) has over 40 years experience in developing electrocardiogram interpretation systems using computers as an expert in the field of electrocardiography, with over 300 publications on this topic and In addition to refereed papers, I am writing numerous books. Professor McFarlane is known as a pioneer on the use of computers in electrocardiogram interpretation at hospitals. The results of the research conducted by the professor’s team have been used commercially and the Glasgow University Electrocardiogram Interpretation and Analysis method developed at the professor’s lab is currently being used around the world. The Glasgow analysis method is installed in the MyoVista® wav ECG ™ Device , which enhances the functions of Heart Sciences products by computer analysis of conventional electrocardiogram waveforms. Professor is currently Emeritus Professor and Honorary Senior Fellow at the University of Glasgow. Professor McFarlane was awarded CBE in 2014 against the achievement of medical treatment in the UK.

Professor is the incumbent president of the international computer electrocardiographical conference (ISCE). I also serve as Chairman of the World Electrochemical Society (ISE) who served as Chairman in the past. What is the main concern in the work experience of the professor is the application of computer techniques to electrocardiogram interpretation.

Professor McFarlane states as follows. “The use of computer skills in Heart Sciences such as signal processing and artificial intelligence is truly innovative and I am looking forward to contributing to the success of Heart Sciences.”

Mark Hilz, Chief Executive Officer of Heart Sciences, says: “Heart Sciences is honored to have Professor McFarlane at the clinical advisory committee. Professor Professor’s extensive experience and expertise on the application of computerized techniques to electrocardiograms will be based on the direction of our technology and future prospects I am very conforming, I would like to cooperate with the professor and achieve the common goal of improving the function to the electrocardiogram method to discover cardiac diseases. ”

About Heart Sciences

Heart Sciences leads innovation in the field of continuous wavelet transform (CWT) signal processing and electrocardiography through the application of artificial intelligence. Wavelet signal processing is currently used in various industries as an important tool for providing detailed knowledge related to spectral analysis of signals and new useful data. Heart Sciences’ MyoVista® Wavelet ECG (wavECG ™) is the market’s first resting 12-lead electrocardiograph with a new informatics technology based on wavelet signal processing. Patented informatics technology focuses on information related to energy rather than conventional data based on voltage. The mission of Heart Sciences is to realize an accurate and easy-to-find screening method for the early detection of heart disease.

MyoVista wavECG装置は、専有的なインフォマティクス技術に加え、世界で最も評価の高い解釈プロセスの1つであるグラスゴーアルゴリズムによる解析を含め、安静時12誘導心電図の機能をフルに備えています。本装置は15.6インチ高解像度タッチスクリーンディスプレーを備え、タブレットデバイスに共通する多くの機能を搭載し、必要なユーザー訓練は最小限で済み、ECGの臨床ワークフローに変更を及ぼしません。MyoVista wavECG装置は現在、米国での市販・流通に供されていません。

ハートサイエンシズは、テキサス州サウスレイクを拠点とする米国の非公開企業です。

詳細情報についてはwww.heartsciences.comをご覧ください。

本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。